Meeting
2018 ASCO Annual Meeting
A phase I study to evaluate safety, tolerability, pharmacokinetics and activity of oraxol in patients (pts) with advanced malignancies.
Authors
Wen Wee Ma
Mayo Clinic, Rochester, MN
Wen Wee Ma , Nilofer Saba Azad , Elaine Tat Lam , Jennifer Robinson Diamond , Grace K. Dy , Mateusz Opyrchal , Denise Gallagher , Caden Brennen , David Cutler , Douglas Kramer , Wing Kai Chan , Rudolf Kwan , Gerald J. Fetterly , Alex A. Adjei , Antonio Jimeno
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Chemotherapy
Clinical Trial Registration Number
NCT01967043
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2526)
DOI
10.1200/JCO.2018.36.15_suppl.2526
Abstract #
2526
Poster Bd #
352
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase I study of nanoparticle albumin-bound sirolimus (NAB-S) combined with pazopanib (PAZO) in patients with advanced soft tissue sarcoma (STS).
First Author: Lee D. Cranmer
Poster
2023 ASCO Annual Meeting
Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.
First Author: Brian Ko
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk
Poster
2020 ASCO Virtual Scientific Program
Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.
First Author: Jasmine Huynh